Abstract
Increasingly real-world evidence (RWE) is also appraised to support the value of new health technologies that ensures timely patient access. RWE is considered as evidence gathered outside of RCTs and derived from data obtained from non-randomized trials, observational studies, or databases amongst others. This analysis aims to assess the value of RWE in recent HTA appraisals for melanoma drugs in England, France, Canada, Australia, Germany, Scotland, and the Netherlands.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
